RESUMEN
Fundamentos: cresce em importância a relação entre níveis glicêmicos aumentados, porém não diabéticos (tolerância à glicose diminuída - TGD), fator de risco cardiovascular e hipertrofia ventricular esquerda (HVE). Objetivo: avaliar a massa do ventrículo esquerdo (MVE) em pacientes hipertensos sob tratamento ambulatorial e com TGD. Materiais e métodos: foram avaliados 358 pacientes hipertensos (com média de idade 59 ± 11 anos), divididos em três grupos: grupo I (hipertensos); grupo II (hipertensos com TGD) e grupo III (hipertensos com diabetes tipo 2). Em todos os pacientes foi realizado o ecocardiograma e utilizada a fórmula de Devereux para o cálculo da massa do ventrículo esquerdo (MVE). Para o índice de MVE (IMVE) foram considerados valores normais de até 89 e 103 g/m² para mulheres e homens, respectivamente. Utilizou-se o teste estatístico ANOVA complementado pelo teste de Tukey e Bonferroni para detectar diferenças entre os grupos. Resultados: a média do IMVE foi de 110,2 ± 33,0; 117,6 ± 30,1 e 128,0 ± 46,8 g/m² nos grupos I, II e III, respectivamente, sendo que 65,1% (grupo I), 74,6% (grupo II) e 80,5% (grupo III) dos pacientes apresentaram aumento do IMVE. Não houve diferença estatística no aumento de IMVE entre os grupos I e II, mas foi significantemente maior no grupo III, quando comparado com o grupo I. Conclusões: o grupo dos pacientes hipertensos com TGD (grupo II) não apresentou aumento de MVE estatisticamente significante em relação aos não intolerantes (grupo I) e o grupo de pacientes hipertensos e diabéticos apresentou aumento significante da MVE em relação ao grupo de hipertensos (grupo I).
Background: It is growing in importance the correlation between elevated glycemic levels (impaired glucose tolerance) but no overt diabetes and the risk factor of cardiovascular disease and increased cardiac mass. Objective: We sought to determine the left ventricular mass (LVM) in hypertensive patients under treatment and with impaired glucose tolerance (IGT). Materials and methods: 358 patients were evaluated (mean age 59 ± 11 years) separated in three groups: group I (hypertension); group II (hypertension and IGT) and group III (hypertension and diabetes mellitus 2). Echocardiograms were performed in all patients and the left ventricular mass index (LVMI) was calculated using the Devereux's criteria and values greater than 110 and 134 g/m² for women and man, respectively, were considered for left ventricular hypertrophy. The statistic methods ANOVA together with Tukey and Bonferroni tests were executed to detect differences among groups. Results: 110,2 ± 33,0; 117,6 ± 31,0 and 128,0 ± 46,8 g/m² were the mean of LVMI for groups I, II and III, respectively. The increasing of LVM was 65,1% (group I), 74,6% (group II) and 80,5% (group III). There was not statistic difference between groups I and II in relation to increasing of LVMI, but it was significantly greater in group III. Conclusions: The increasing of LVMI was not observed in the impaired glucose tolerance hypertensive patients when compared with normoglycemic hypertensive patients and the increasing of LVMI was significant in diabetic hypertensive patients.
Asunto(s)
Humanos , Masculino , Femenino , Adulto , Persona de Mediana Edad , Anciano , Anciano de 80 o más Años , Diabetes Mellitus , Hipertensión , Hipertrofia Ventricular IzquierdaRESUMEN
OBJECTIVE: To report about a group of physicians' understanding of the recommendations of the II Brazilian Guidelines Conference on Dyslipidemias, and about the state of the art of primary and secondary prevention of atherosclerosis. METHODS: Through the use of a questionnaire on dyslipidemia, atherosclerosis prevention, and recommendations for lipid targets established by the II Brazilian Guidelines Conference on Dyslipidemias, 746 physicians, 98 percent cardiologists, were evaluated. RESULTS:Eighty-seven percent of the respondents stated that the treatment of dyslipidemia changes the natural history of coronary disease. Although most of the participants followed the total cholesterol recommendations (<200mg/dL for atherosclerosis prevention), only 55.8 percent would adopt the target of LDL-C <100 mg/dL for secondary prevention. Between 30.5 and 36.7 percent answered, in different questions, that the recommended level for HDL-C should be <35mg/dL. Only 32.7 percent would treat their patients indefinitely with lipid- lowering drugs. If the drug treatment did not reach the proposed target, only 35.5 percent would increase the dosage, and 29.4 percent would change the medication. Participants did not know the targets proposed for diabetics. CONCLUSION: Although the participating physicians valued the role played by lipids in the prevention of atherosclerosis, serious deficiencies exist in their knowledge of the recommendations given during the II Brazilian Guidelines Conference on Dyslipidemias